Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Sandoz
Information provided by (Responsible Party):
Sandoz Identifier:
First received: January 10, 2013
Last updated: January 16, 2013
Last verified: January 2013

Data collection on the safety and efficacy of Zarzio® / Filgrastim HEXAL® in adult healthy unrelated stem cell donors undergoing peripheral blood progenitor cell mobilization.

Peripheral Blood Progenitor Cell Mobilization With G-CSF

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Incidence of drug-related adverse events following mobilization with Sandoz' filgrastim. [ Time Frame: each patient will be followed for 10 years after mobilization ] [ Designated as safety issue: No ]
    The primary objective is to investigate adverse events that are suspected to be related to stem cell mobilization with the Sandoz' filgrastim in healthy unrelated donors.

Secondary Outcome Measures:
  • Efficacy assessment in terms of the CD34+ cell count. [ Time Frame: CD34+ cells are counted on 1 day immediately preceding apheresis ] [ Designated as safety issue: No ]
    The secondary objective is to investigate the efficacy of stem cell mobilization with the Sandoz' filgrastim in terms of the CD34+ cell count.

Estimated Enrollment: 200
Study Start Date: May 2011
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

adult, unrelated, healthy volunteers who received at least one dose of Sandoz' filgrastim


Inclusion Criteria:

  • none

Exclusion Criteria:

  • Related to recipient
  • Chronic significant organ diseases
  • Systemic autoimmune diseases
  • Chronic infectious diseases
  • History of malignant disease
  • Pregnant and breastfeeding women
  • Hypersensitivity to E. coli derived proteins
  • Hypersensitivity to the active substance or to any of the excipients of the Sandoz' filgrastim
  • Absolute and relative contraindications as specified in the summary of product characteristics of the Sandoz` filgrastim
  • Participation in previous stem cell mobilization procedures
  • Previous or concurrent use of other mobilising agents, e.g. plerixafor
  • Donor is unwilling to give written informed consent to his/her study participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01766934

Contact: Sandoz +49 8024 476 ext 0

German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen Recruiting
Frankfurt/Main, Hessen, Germany, 60528
Contact: Halvard Bönig, M.A., MD         
Sponsors and Collaborators
Principal Investigator: Halvard Bönig, Dr. med, M.A., MD Blood Donor Service Baden-Wuerttemberg Hessen
Study Chair: Halvard Bönig, Dr. med. M.A., MD Blood Donor Service Baden-Wuerttemberg Hessen
  More Information

No publications provided

Responsible Party: Sandoz Identifier: NCT01766934     History of Changes
Other Study ID Numbers: EP06-501
Study First Received: January 10, 2013
Last Updated: January 16, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Sandoz:
Peripheral blood progenitor cell (PBPC) mobilization
allogenic hematopoetic stem cell transplantation (HSCT)
recombinant human granulocyte colony stimulating factor (rhG-CSF)

Additional relevant MeSH terms:
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions processed this record on September 22, 2014